Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Joshua Stevenson-Hoare"'
Autor:
Kira Trares, Hannah Stocker, Joshua Stevenson-Hoare, Laura Perna, Bernd Holleczek, Konrad Beyreuther, Ben Schöttker, Hermann Brenner
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Polygenic risk scores (PRS) and subjective cognitive decline (SCD) are associated with the risk of developing dementia. It remains to examine whether they can improve the established cardiovascular risk factors aging and dementia
Externí odkaz:
https://doaj.org/article/2dd30935939c4e65bc30c566b652366b
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 16, Iss 3, Pp n/a-n/a (2024)
Abstract INTRODUCTION Subjective hearing and memory problems are detectable earlier than objective measures of sensory loss and cognitive decline, which are known to be related to an increased risk of dementia in later life. METHODS Using a populatio
Externí odkaz:
https://doaj.org/article/ee4d5e526b304421a51eb9c102366297
Autor:
Valentina Escott-Price, Michael J Owen, George Kirov, Jun Han, Joshua Stevenson-Hoare, Sophie E Legge, Emily Simmonds, Michael O’Donovan
Publikováno v:
BMJ Mental Health, Vol 27, Iss 1 (2024)
Background Individuals with psychiatric disorders have an increased risk of developing dementia. Most cross-sectional studies suffer from selection bias, underdiagnosis and poor population representation, while there is only limited evidence from lon
Externí odkaz:
https://doaj.org/article/2ccddd154d294e579bb786009c2e76c5
Autor:
Aurora Veteleanu, Joshua Stevenson-Hoare, Samuel Keat, Nikoleta Daskoulidou, Henrik Zetterberg, Amanda Heslegrave, Valentina Escott-Price, Julie Williams, Rebecca Sims, Wioleta M. Zelek, Sarah M. Carpanini, Bryan Paul Morgan
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-18 (2023)
Abstract Background Alzheimer’s disease (AD) has been associated with immune dysregulation in biomarker and genome-wide association studies (GWAS). GWAS hits include the genes encoding complement regulators clusterin (CLU) and complement receptor 1
Externí odkaz:
https://doaj.org/article/59f3ff05f56e42c9a86a2a9c929c0db9
Publikováno v:
BMC Public Health, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Metformin, a medication for type 2 diabetes, has been linked to many non-diabetes health benefits including increasing healthy lifespan. Previous work has only examined the benefits of metformin over periods of less than ten years
Externí odkaz:
https://doaj.org/article/4a982ecf9e4842b5976d708ac6fc9537
Autor:
Ganna Leonenko, Emily Baker, Joshua Stevenson-Hoare, Annerieke Sierksma, Mark Fiers, Julie Williams, Bart de Strooper, Valentina Escott-Price
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
While polygenic risk scores have been shown to be correlated with disease risk, there is little agreement on how the score should be calculated. Here the authors investigate risk scores for Alzheimer’s disease, finding that the most effective appro
Externí odkaz:
https://doaj.org/article/4d36e2473d584250a235b7a2b478f9c3
Publikováno v:
Neurobiology of Disease, Vol 142, Iss , Pp 104953- (2020)
In this paper we explore the phenomenon of pleiotropy in neurodegenerative diseases, focusing on Alzheimer's disease (AD). We summarize the various techniques developed to investigate pleiotropy among traits, elaborating in the polygenic risk scores
Externí odkaz:
https://doaj.org/article/c58b1c0dc21141629b5d96850b9a7548
Autor:
Joshua Stevenson-Hoare, Amanda Heslegrave, Ganna Leonenko, Dina Fathalla, Eftychia Bellou, Lauren Luckcuck, Rachel Marshall, Rebecca Sims, Bryan Paul Morgan, John Hardy, Bart de Strooper, Julie Williams, Henrik Zetterberg, Valentina Escott-Price
Publikováno v:
Brain. 146:690-699
Plasma biomarkers for Alzheimer’s disease-related pathologies have undergone rapid developments during the past few years, and there are now well-validated blood tests for amyloid and tau pathology, as well as neurodegeneration and astrocytic activ
Background Metformin, a medication for type 2 diabetes, has been linked to many non-diabetes health benefits including increasing healthy lifespan. Previous work has only examined the benefits of metformin over periods of less than ten years, which m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e69b009d5472ba2d7942d4a181a6084
https://doi.org/10.21203/rs.3.rs-2297890/v1
https://doi.org/10.21203/rs.3.rs-2297890/v1
Autor:
Emily Baker, Bart De Strooper, Joshua Stevenson-Hoare, Ganna Leonenko, Annerieke Sierksma, Julie Williams, Valentina Escott-Price, Mark Fiers
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Polygenic Risk Scores (PRS) for AD offer unique possibilities for reliable identification of individuals at high and low risk of AD. However, there is little agreement in the field as to what approach should be used for genetic risk score calculation